Review

History of Acute Promyelocytic Leukemia

Miguel A. Sanz1,2, Eva Barragán2,3

1Department of Hematology, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
2Clinical Laboratory, Hospital Universitari i Politécnic La Fe, Valencia, Spain
3Centro de Investigación Biomédica en Red de Cáncer, Carlos III Institute, Madrid, Spain

ARTICLE INFO

Article History
Received 11 April 2021
Accepted 03 June 2021

Keywords
Acute promyelocytic leukemia
arsenic trioxide
all-trans retinoic acid

ABSTRACT

In this article, we discuss the history of acute promyelocytic leukemia (APL) from the pre-therapeutic era, which began after its recognition by Hillestad in 1947 as a nosological entity, to the present day. It is a paradigmatic history that has transformed the “most malignant leukemia form” into the most curable one. The identification of a balanced reciprocal translocation between chromosomes 15 and 17, resulting in fusion between the promyelocytic leukemia gene and the retinoic acid receptor alpha, has been crucial in understanding the mechanisms of leukemogenesis, and responsible for the peculiar response to targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). We review the milestones that marked successive therapeutic advances, beginning with the introduction of the first successful chemotherapy in the early 1970s, followed by a subsequent incorporation of ATRA and ATO in the late 1980s and early 1990s which have revolutionized the treatment of this disease. Over the past two decades, treatment optimization has relied on the combination of ATRA, ATO, and chemotherapy according to risk-adapted approaches, which together with improvements in supportive therapy have paved the way for cure for most patients with APL.

1. INTRODUCTION

Paraphrasing Bernard [1], the exciting history of acute promyelocytic leukemia (APL) is marked by a series of efforts to combat existing dogmas in cancer. In recent years, APL has become a paradigm that has opened new paths for the treatment of not only other leukemias, but many other forms of cancer.

In the history of APL, we can schematically recognize the following periods: (1) The pre-therapeutic era (1940–1973), in which the promyelocytic cell achieved full recognition for the first time, followed by APL being considered as a unique nosological entity some years later; (2) The chemotherapy era (1973–1988), in which important advances were also made in the biological and genetic characterization of this peculiar leukemia; (3) The modern era (1988–present), in which the advent of all-trans retinoic acid (ATRA) and later arsenic trioxide (ATO) have revolutionized the treatment of APL. During this period, progress has been remarkable through the implementation of strategies that have optimized the combination of the three fundamental agents in this disease: ATRA, ATO and chemotherapy. Figure 1 shows the most important milestones that have marked the history of APL and paved the way for the cure of most patients with this disease.

© 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

2. THE PRE-THERAPEUTIC ERA

2.1. Recognition of the Promyelocyte as a Cellular Entity and APL as a Nosological Entity

Although the term promyelocyte had already been used years before by Pappenheim [2], it was not until 1940 that a permanent recognition of this cell occurred after the excellent description made by the Italian-Spanish Pittaluga [3]. After that, the next milestone was the recognition of APL as a nosological entity. The merit must be attributed to the Norwegian Hillestad [4], who, in a short and precise article, described the disease in three patients characterized by “a very rapid fatal course of only a few weeks duration”, a leukocyte picture dominated by the presence of promyelocytes, and a tendency to severe bleeding due to fibrinolysis and thrombocytopenia. Hillestad also observed a normal erythrocyte sedimentation rate, probably caused by a low plasma fibrinogen concentration. His conclusion was, therefore, that “APL appears to be the most malignant form of acute leukemia.” He was right, referring to the natural history of this disease, since at that time there was a lack of any effective form of treatment. Fortunately, as we will discuss later, the natural history of APL would begin to change with the first therapeutic successes reported by Bernard et al. [5]. Returning to Hillestad’s study, he should also be credited with introducing the term by which this
peculiar form of acute myeloid leukemia (AML) has been known since then, when he said “a logical name for this type of leukemia is acute promyelocytic leukemia”. Almost simultaneously, a relationship between promyelocytic proliferation and a hemorrhagic syndrome in patients with leukemia was found by Bernard’s group in Paris [6]. A couple of years later, this group described in more detail the features of APL in a series of 20 patients [7]. They confirmed the hyperacute course of APL, with abundant mucocutaneous hemorrhage that led to death due to cerebral hemorrhage in a high proportion of patients. The malignant cells in the blood and bone marrow of patients with APL had a characteristic morphology along with severe fibrinolysis and hypofibrinogenemia. Typically, malignant cells were much more abundant in bone marrow than in peripheral blood, where white blood cell counts were typically low. These malignant cells were described as abnormal promyelocytes with a characteristic pattern of heavy granulation, often reniform or bilobed immature nucleus, and a large cytoplasm with abundant azurophilic granulation, sometimes nearly covering the nucleus. Many of these cells contained characteristic formations in the cytoplasm, called Auer rods, which often formed bundles (“faggots”). Several years later, this morphological description was adopted and refined in the first French–American–British classification proposed in 1976, assigning this entity the M3 subtype among the eight recognized subtypes of AML [8].

3. THE ERA OF CHEMOTHERAPY AND GENETIC CHARACTERIZATION OF APL

3.1. Advances in Chemotherapy and Supportive Therapy

The introduction of chemotherapy for APL was the first turning point that dramatically changed the natural course of the disease. Since the landmark article by Bernard et al. [5], when they reported the first successful results with high-dose daunorubicin, chemotherapy for this leukemia has essentially been based on two main approaches: (1) AML-like chemotherapy, generally based on the combination of an anthracycline and cytarabine; and (2) Tailored therapy for APL, generally based on monotherapy with high-dose anthracycline. The latter was the strategy adopted by most groups in Europe. Most of the studies in the literature reported a high rate of complete remission (CR), ranging from 47% to 88% (Table 1). They also showed a higher rate of fatal bleeding and a lower rate of primary resistance compared to other subtypes of AML. The latter indicates a peculiar sensitivity of APL blasts to anthracyclines, which, in turn, is most likely related to absent or low expression of multidrug resistance mediated by the p170 glycoprotein and other minimal residual disease (MRD)-associated molecules [9–11]. Taken together, the results obtained by combining an anthracycline to cytarabine did not appear to improve CR rates (Table 1). It should be noted, however, that the only available randomized study comparing idarubicin alone with idarubicin plus cytarabine, carried out by the Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) group in the pre-ATRA era, showed better results with idarubicin alone in terms of event-free survival, although no difference was observed in the CR rate [12].

For post-remission therapy during the pre-ATRA era, a variety of approaches were used, usually mimicking the strategy used for other AML subtypes. Thus, initial studies included consolidation courses of moderate intensity (re-inductions) with or without maintenance treatment. This approach was progressively changed with the introduction of higher intensity regimens, including autologous and allogeneic stem cell transplantation (SCT), as for the other AML subtypes. An European survey of SCT in APL analyzed the outcome of patients reported to the European society for Blood and Marrow Transplantation registry between November 1979 and December 1992 (mainly the period before ATRA in Europe) [13]. That study showed that both autologous and allogeneic transplantation were performed primarily in CR1 (69% and 81%, respectively) and roughly 45% of APL patients were cured by SCT. Although this treatment approach was still used for some years after the introduction of ATRA, the outstanding results obtained with the combination of ATRA and chemotherapy soon discouraged the use of SCT in first-line treatment. In fact, SCT has virtually ceased to play any role in CR1 and has been relegated to consolidation for patients in CR2 or beyond after salvage therapy for relapsed APL [14–17].

During that period, it is also interesting to mention two studies that suggested a survival advantage in patients with APL when they
Table 1  Main reported series of APL treated with chemotherapy alone

| References                  | No. of patients | CR (%) |
|-----------------------------|-----------------|--------|
| Daunorubicin alone          |                 |        |
| Bernard et al. [5]          | 34              | 55     |
| Marty et al. [18]           | 83              | 64     |
| Peti et al. [118]           | 30              | 67     |
| Sanz et al. [119]           | 34              | 68     |
| Rodeghiero et al. [120]     | 126             | 67     |
| Fenaux et al. [121]         | 35              | 88     |
| Idarubicin alone            |                 |        |
| Avvisati et al. [122]       | 27              | 81     |
| Avvisati et al. [12]        | 131             | 76     |
| Anthracyline + Ara-C ± other|                 |        |
| Ruggiero et al. [123]       | 13              | 54     |
| Daly et al. [124]           | 15              | 73     |
| Arlin et al. [125]          | 16              | 75     |
| Cordonnier et al. [126]     | 57              | 53     |
| Kantarjian et al. [19]      | 60              | 53     |
| Goldberg et al. [127]       | 27              | 74     |
| Hoyle et al. [128]          | 115             | 60     |
| Cunningham et al. [129]     | 57              | 72     |
| Rodeghiero et al. [120]     | 142             | 58     |
| Thomas et al. [130]         | 67              | 49     |
| Fenaux et al. [131]         | 21              | 86     |
| Head et al. [132]           | 18              | 66     |
| Willemze et al. [133]       | 45              | 71     |

were administered maintenance treatment with 6-mercaptopurine and methotrexate [18,19].

Significant advances in supportive therapy over that period, particularly in the management of infections and transfusion support, resulted in increased CR rates by decreasing mortality from infection or bleeding during induction. In particular, massive transfusion of platelets and fresh plasma have been the cornerstone that has supported the prevention and treatment of bleeding diathesis in APL. Other measures, such as the use of heparin, tranexamic acid or other anticoagulant or antifibrinolytic treatments have not shown benefit to decrease the bleeding risk associated with APL coagulopathy and, therefore, are not currently recommended [14,15].

3.2. First Steps in Understanding the Biology and Genetics of APL

During the pre-ATRA era, there were several major breakthroughs on the biology and genetics of APL, such as the discovery of the t(15;17) translocation, the identification of the promyelocytic leukemia retinoic acid receptor alpha (PML-RARA) fusion gene resulting from this cytogenetic alteration, and the development of in vitro studies demonstrating the possibility of reversing malignancy by inducing differentiation of myeloid leukemia.

A chromosome abnormality in APL was first reported by the University of Chicago group led by Rowley, which was primarily interpreted as a partial deletion of the long arm of chromosome 17 [20]. A year later, that group discovered that it was actually a reciprocal translocation between the long arms of chromosomes 15 and 17 [21,22]. After a period of controversy about the specificity of this chromosome alteration, and the possibility of geographic differences in the incidence of this alteration in APL patients [23,24], the University of Chicago’s group definitively established that the t(15;17) with breakpoints at 15q22 and 17q21.1 may be found in every APL patient if optimal chromosome analysis is performed [25]. Today we know that, apart from the methodological flaws in cytogenetic studies, which were very common at that time, some patients have cryptic translocations with insertions or other more complex chromosomal exchanges that make detection of the t(15;17) difficult [26,27].

The discovery of the specific t(15;17) chromosomal translocation in APL contributed to the recognition of a less differentiated variant called microgranular, or M3 variant, a few years later [28]. This morphological variant, which accounts for approximately one third of APL cases, typically presents with leukocytosis with numerous circulating abnormal promyelocytes, but has the same cytogenetic and molecular features as the classical hypergranular APL (M3).

At the very beginning of the 90s, just in the transition period to the ATRA era, another crucial advance took place in the genetic characterization of APL, the discovery and cloning of the PML-RARA rearrangement, whose historical significance is unquestionable. The precedent for this discovery was the identification of the RARA gene at the 17q21 breakpoint implicated in the t(15;17) [29]. Cloning and sequencing of the RARA gene and its breakpoint is attributed to three research teams led, respectively, by de Thé et al. [30], Solomon et al. [31] and Pellici [32], who published their studies almost simultaneously in the early 1990s. A year later, the PML gene (originally named MYL), located on chromosome 15q22, was completely sequenced by de Thé et al. [33] and Kakizuka et al. [34], who also simultaneously published their discovery in the same issue of Cell. It was later shown that this gene participates in the control of cell proliferation, apoptosis and senescence [35]. The cloning of the t(15;17) also enabled the design of polymerase chain reaction (PCR)-based strategies not only for a rapid diagnosis, but also for sensitive detection of MRD [36–40].

The circumstances that led to the use of ATRA as a treatment for APL have been extensively described by some of the protagonists of this story [41,42]. Certainly, some pioneering studies had suggested the in vitro differentiation capacity of teratocarcinoma cells [43] and, 10 years later, of neuroblastoma cells [44], as well as of a murine virus-induced erythroleukemia cell line when stimulated with dimethyl sulfoxide [45]. However, the greatest inspiring advance of differentiation therapy in leukemias was made by Sachs [46], who discovered that leukemic cells could be induced to differentiate under the action of certain agents, contradicting the dogma of the irreversibility of the leukemic cell. In the following years, a wide variety of agents, including retinoic acid, a derivative of vitamin A, demonstrated their ability to induce morphological and functional maturation of myeloid cells of the HL-60 line [47,48]. This cell line has many features in common with APL cells, but it does not carry the t(15;17) and only has one chromosome 17. Likewise, leukemic cells from patients with APL (M3) differentiate in vitro in the presence of retinoids [47,48]. These laboratory investigations did not take long to lead to anecdotal observations of patients with APL who showed clinical improvement or even CR, along with promyelocyte maturation (differentiation), when treated with 13-cis retinoic acid, a retinoic acid isomer other than ATRA [49–51].
In 1985, during an informal meeting of researchers from Shanghai with Laurent Degos of the Institute of Hematology at Saint Louis Hospital in Paris, the feasibility of treating leukemia by inducing differentiation with ATRA and/or low-dose cytosine arabinoside was raised and discussed. A few months later on that same year, given the availability of ATRA, just approved by the Shanghai Municipality for the treatment of skin diseases such as psoriasis and acne, the Shanghai group decided to try it in a 5-year-old girl with refractory APL [41]. Three weeks later, the girl achieved CR and received post-remission treatment with alternating ATRA and chemotherapy for one year. Since then, she has been in continuous CR. The success of this case encouraged further testing of the drug in other cases of APL, which marked the beginning of the ATRA era and represented the first model of targeted therapy for cancer.

4. THE ERA OF ATRA – OPTIMIZATION OF THE COMBINATION WITH CHEMOTHERAPY

The extension of the use of ATRA alone to six cases of APL (four newly diagnosed and two refractory to chemotherapy), reaching CR in all of them, was reported in 1987 in a Chinese journal [52]. However, it was not until a year later that the impressive results obtained by the Shanghai Institute of Hematology in 24 patients with APL (16 newly diagnosed and eight refractory cases) treated with ATRA alone were released to the rest of the world [41]. All patients achieved CR, but one required the addition of low-dose cytosine arabinoside to ATRA. From a privileged position, as one of the protagonists in the history, Degos [42] describes in his article “the history of APL” how they faced the challenge of treating the first APL patients with ATRA in France.

4.1. Early Results with ATRA Alone without Further Chemotherapy

After the seminal report by the Shanghai group [53], a few additional studies confirmed the efficacy of ATRA alone to achieve CR in patients with APL (Table 2). These confirmatory studies were carried out by a select group of institutions in the world, the Shanghai Institute of Hematology [54], the Jiangsu Institute of Hematology [55], the Hospital Saint-Louis in Paris [56,57], and the Memorial Sloan Kettering Cancer Center in New York [58]. Apart from the high rates of CR, all these studies described some differential features of induction with ATRA compared to chemotherapy. In contrast to chemotherapy, the administration of ATRA did not produce aplasia or alopecia, with few infections and a rapid improvement in coagulopathy. The gradual terminal differentiation of malignant promyelocytes in the bone marrow was also a very striking cytomorphological feature. However, it was soon found that patients who achieved CR generally relapsed within a few months, despite continuous ATRA treatment (median 5 months). This observation inspired the need to implement modifications in the therapeutic strategy.

4.2. ATRA Alone Followed by Chemotherapy

Following the initial experience with ATRA alone, a randomized trial [59] and several non-randomized studies [60–63] conducted in the early 1990s showed that patients receiving ATRA followed by anthracycline-based chemotherapy (with or without cytarabine) did significantly better, in terms of either CR or relapse rates, than those treated with ATRA alone or chemotherapy alone. The randomized study conducted by the European APL group (APL91) compared chemotherapy alone (daunorubicin plus cytarabine) with ATRA followed by chemotherapy [59]. Although differences in the CR rate were not significant, the study was terminated early because of a significantly lower relapse rate and superior disease-free survival in the ATRA followed by chemotherapy arm. Those results were confirmed in successive analyses with a longer follow-up [64,65]. Subsequently, other randomized [66], but also non-randomized studies [67,68] in which chemotherapy was given after ATRA induction confirmed the advantage of this strategy compared to either ATRA or chemotherapy alone (Table 3).

4.3. ATRA plus Chemotherapy

The simultaneous combination of ATRA and chemotherapy was shown to be superior to their sequential administration (ATRA followed by chemotherapy) in a randomized study of the European APL group [69]. The advantage of this approach was further confirmed in other large, uncontrolled, multicenter trials carried out during the second half of the 90s [68,70–75] (Table 4). Based on these studies, the European LeukemiaNet established the combination of ATRA plus anthracycline-based chemotherapy for induction, followed by 2–3 courses of anthracycline-based chemotherapy for consolidation, as the standard of care for newly diagnosed APL [14].

Table 2 Induction treatment with ATRA alone for APL

| References     | ATRA dose (mg/m²) | No. of patients | CR (%) | Relapse |
|----------------|------------------|----------------|--------|---------|
| Huang et al. [53] | 45–100          | 24*            | 100    | 8       |
| Degos et al. [56] | 45              | 20             | 95     | 9       |
| Castaigne et al. [57] | 45–100      | 22             | 64     | 9       |
| Wang et al. [54]  | 45–100           | 57             | 84     | NA      |
| Warrell et al. [58] | 45              | 11             | 82     | 1       |
| Chen et al. [55]  | 60–80            | 50             | 94     | 19      |

*Low-dose Ara-C was added to one patient. NA, not available.

Table 3 Studies with ATRA alone for induction followed by chemotherapy

| References     | No. of patients | Anthracycline | CR (%) | OS (%) |
|----------------|-----------------|---------------|--------|--------|
| Fenaux et al. [59] | 54             | DNR           | 95     | 76     | 4 years |
| Frankel et al. [67] | 34             | IDA           | 86     | 70     | 3 years |
| Tallman et al. [66] | 172            | DNR           | 72     | 71     | 3 years |
| Asou et al. [68] | 62              | DNR, ACR, MTZ | 88     | 74     | 4 years |
| Fenaux et al. [69] | 109             | DNR           | 95     | 81     | 2 years |

ATRA 45 mg/m²/day; ACR, aclarubicin; DNR, daunorubicin; IDA, idarubicin; MTZ, mitoxantrone; OS, overall survival.
### 4.4. Definition of Relapse-Risk Categories and Adoption of Risk-Adapted Strategies

The results obtained with the simultaneous administration of ATRA and chemotherapy provided an important source for the investigation of prognostic factors to be used for treatment stratification. In this regard, the definition of relapse risk in a joint study of the GIMEMA and Programa Español de Tratamientos en Hematología (PETHEMA) groups was critical for the design of risk-adapted strategies [70,71,73,74]. In this way, a gradual intensity could be given to intensify treatment only in patients at higher risk of relapse, while a reduction in the dose-intensity of chemotherapy in patients with lower risk could reduce toxicity without compromising cure rates. The results of both GIMEMA and PETHEMA studies using such approach showed significant improvement of outcome [75–78]. Since then, there is a tendency to design risk-adapted strategies to modulate treatment intensity in consolidation according not only to age, assuming that older patients are more vulnerable to toxicity, with higher rates of neutropenic sepsis and increased treatment-related mortality, but also to predefined risk factors for relapse, particularly presenting high WBC counts [15,16].

Another interesting strategy for tailoring post-remission treatment that has been proposed is the use of a reliable sequential real-time quantitative PCR (RQ-PCR) monitoring of PML-RARA [79]. Encouraging results have been reported with such strategy when coupled with pre-emptive therapy (MRD-driven therapy), but it remains to be established whether this approach can be considered today as a standardized, cost-effective, and universally available method for routine laboratories.

### 4.5. Understanding the Molecular Mechanisms involved in APL Leukemogenesis and Response to Targeted Therapy

After the genetic studies reported in the early 1990s, the availability of cell lines and transgenic mouse models harboring the PML-RARA fusion gene promoted research on APL leukemogenesis, and unraveled the molecular mechanisms involved in the transcriptional repression induced by the PML-RARA protein, as well as the response to ATRA and ATO [80–83]. Several subsequent studies have led us to know that the oncogenic activity of PML-RARA is exerted through both dominant-negative and gain-of-function effects [84,85]. The PML-RARA fusion protein maintains the ability to multimerize with various classes of proteins, enhancing their binding to corepressors and acting as a super-repressor insensitive to physiological concentrations of ATRA [83,86]. Thus, PML-RARA represses the transcription of several genes involved in myeloid differentiation through the altered recruitment of histone deacetylases [87]. In addition, PML-RARA–RXR complexes mainly recognize atypical RARA and interact with genomic regions, which confers a proliferative and survival advantage to leukemic cells [88,89].

A few years later, the mechanisms involved in the response to targeted therapy with ATRA, but also with ATO, which are capable of restoring PML-RARA functions, have also been unraveled. Thus, ATRA induces proteasome-mediated PML-RARA degradation and transcriptional activation as a consequence of the release of various corepressors and interaction with a series of coactivators [90,91], while ATO induces post-transcriptional modifications in the second B box (B2) domain of the PML moiety, which results in the restoration of nuclear bodies (NB) and PML-RARA degradation [92,93].

### 4.6. Advances in the Management and Supportive Therapy

In addition to the improvements that occurred in the management of patients with acute leukemia in general, mainly in transfusion support as well as in the prevention and treatment of infections, some others specifically benefited patients with APL, such as the recognition of the differentiation syndrome and its easy reversibility when it is treated early and appropriately, and a better understanding of the ATRA catabolic process, among others.

Although cases in which an increase in leukocytes was accompanied by fever and dyspnea, and occasionally kidney failure, had already been reported among the first patients treated with ATRA [57], it was in 1992 when the differentiation syndrome (DS), originally described as retinoic acid syndrome, was first defined [53]. The full-blown syndrome is characterized by unexplained fever, weight gain, peripheral edema, dyspnea with interstitial pulmonary infiltrates, pleuropericardial effusion, hypotension, and acute renal failure. Today we know that, in the context of treatment with ATRA plus chemotherapy, approximately a quarter of patients present some symptom or sign of this syndrome [94], whereas the incidence may be somewhat higher with the combination of ATRA plus ATO. Since the New York group reported an excellent response to corticosteroids [53], the early administration of dexamethasone has become the cornerstone for the management of DS and decrease the DS-associated mortality to 1% [94].

Another very interesting aspect that has contributed to optimizing treatment with ATRA was the early observation that patients treated only with this agent achieved short-term remissions, but that after a therapeutic pause it could occasionally be observed that resistance was reversible [62]. The most widely accepted hypothesis is that this resistance was probably due, in almost all patients, to a catabolic process that reduces the concentration of ATRA in the body. In fact, pharmacological studies were able to demonstrate a substantial decrease in ATRA plasma levels after only a few days
of treatment, remaining at low levels even if the dose was significantly increased [95]. Moreover, it was shown that ATRA induces an increase in the cytochrome P450 activity which, in turn, is also involved in the catabolism of ATRA. These findings led to combine ATRA with chemotherapy and use ATRA intermittently rather than continuously in maintenance therapy.

Historically, the advances in the management of APL coagulopathy must also be highlighted. Physicians soon realized that chemotherapy exacerbated bleeding diathesis and signs of coagulopathy and, therefore, the risk of early death. Whether the coagulopathy of APL is due to a disseminated intravascular syndrome with reactive fibrinolysis, to a primary fibrinolysis, or both pathogenetic mechanisms simultaneously, is still a matter of controversy. Beyond the pathogenesis of APL-associated coagulopathy, massive transfusion of platelets and fresh plasma have been the most effective tool for the prevention and treatment of bleeding diathesis in APL.

In his excellent historical review, Degos describes how the spectacular advances produced from the mid-1980s to the early 1990s, both in the field of therapy and in the understanding of many biological aspects of APL, led Mandelli to organize a first international meeting in Rome in 1993, under the title “APL - A curable disease?”. Since then, every 4 years, this meeting in Rome has become the most important international scientific summit to review the continuous advances in this disease.

5. THE ERA OF ATO

5.1. Early Results with ATO Alone

The introduction of arsenic derivatives in the treatment of APL, as occurred with ATRA, was made in China. In the early 1970s, a group from Harbin Medical University in Manchuria identified ATO as a potential anticancer drug, and began to use an arsenic compound to treat a variety of malignancies. But it was not until 1992, that this group reported that 21 out of 32 patients with APL entered CR with an impressive 30% survival rate after 10 years with Ailing-1 (anticancer-1 or Al-1), an anticancer solution containing 1% ATO [96]. These results were subsequently confirmed by the Shanghai group [97–99].

5.2. Confirmation of ATO as Standard Treatment for Relapsed APL

The impressive results from pioneering studies carried out in China encouraged the design of a pilot study conducted at Memorial Sloan Kettering Cancer Center in New York, which confirmed the effectiveness of ATO in inducing CR in 11 of 12 patients with relapsed APL after extensive prior therapy [100]. These results prompted a multicenter trial in the USA in which ATO was administered as salvage therapy in relapsed patients after ATRA and anthracycline-based chemotherapy [101]. Thirty-four of 40 patients (85%) achieved CR with ATO alone and 86% achieved molecular CR after consolidation therapy. These results established ATO as a highly effective therapy for relapsed APL patients and led to the approval of this drug by the FDA in September 2000 for the treatment of relapse/refractory APL.

5.3. The First Pilot Studies with ATO-based Regimens for Newly Diagnosed APL

Encouraged by the results with ATO in relapsed patients, the Harbin and Shanghai groups expanded the use of this agent to newly diagnosed patients with APL with promising results [99,102]. On the basis of this experience, a few pilot studies in newly diagnosed APL patients treated with ATO alone or in combination with ATRA were carried out in China [103], Iran [104], India [105], and the USA [106]. The CR rate in these studies ranged from 86% to 95%. However, it should be noted that ATO was combined with ATRA [103,106] and/or chemotherapy [103,105] and/or gemtuzumab ozogamicin [106] in a variable proportion of patients, particularly those presenting with hyperleukocytosis (Table 5).

5.4. Confirmation of ATO-based Approach as Standard Treatment for Newly Diagnosed APL

Despite the high efficacy reported in the studies mentioned above, the 2009 European LeukemiaNet recommendations highlighted the absence of properly designed comparative studies of ATO-based versus the standard ATRA plus chemotherapy approach in terms of efficacy, safety, and cost-effectiveness [69]. Therefore, the recommendation was that, in the meantime, the use of ATO-based regimens should be restricted to patients included in clinical trials or for those in whom chemotherapy (especially anthracyclines) was contraindicated. It was also recognized that, in countries where locally produced arsenic compounds provide a more affordable treatment approach than ATRA plus chemotherapy, a cheaper ATO, produced under good quality control, would be effective in curing many patients with APL.

Two multicenter phase 3 trials were set up to compare the efficacy and safety of ATRA plus ATO versus ATRA plus chemotherapy [107,108]. One trial was conducted by the Italian cooperative

| Table 5 | First pilot studies with ATO-based regimens for newly diagnosed APL patients |
| References | No. of patients | Induction therapy | CR (%) | DFS (%) |
| --- | --- | --- | --- | --- |
| Zhang et al. [102] | 30 | ATO | 73 | NA |
| Niu et al. [99] | 11 | ATO ± CHT | 73 | 100 (1 year) |
| Shen et al. [103] | 41 | ATO ± ATRA | 90–95 | 87–100 (2 years) |
| Ghavamzadeh et al. [104] | 94 | ATO | 86 | 64 (2 years) |
| Mathews et al. [105] | 72 | ATO | 86 | 87 (3 years) |
| Estey et al. [106] | 44 | ATO + ATRA ± CHT | 89 | 84 (2 years)* |

*Relapse-free survival. CHT, chemotherapy; DFS, disease-free survival.
GIMEMA in collaboration with the German-Austrian AML Study Group and Study Alliance Leukemia cooperative group, and compared ATRA plus ATO versus ATRA plus chemotherapy (AIDA regimen) in patients with low-to-intermediate risk APL (WBC count ≤10 × 10⁹/L) [107]. The other randomized trial conducted by the National Cancer Research Institute cooperative group included all relapse risk categories [108]. Based primarily on the results of these two randomized trials and the long-term results of a nonrandomized study conducted at the MD Anderson Cancer Center in Houston [109], the combination of ATRA plus ATO has been adopted worldwide as the new standard of care for patients with non-high-risk APL (WBC count ≤10 × 10⁹/L) [15,16,110,111].

6. CURRENT PERSPECTIVES AND FUTURE DIRECTION

Once the extraordinary advances toward the cure of APL have been consolidated, two important issues remain to be resolved in a small fraction of patients with APL: early death and relapse. While these great challenges are solved, some other advances, whose development is quite predictable, could be incorporated into clinical practice in the short or medium term. Among them is the optimization of treatment in patients at high risk of relapse, seeking the most appropriate combination of the three currently available agents, ATRA, ATO, and chemotherapy. The use of oral arsenic derivatives instead of intravenous ATO is already a reality in China, and we can envisage that sooner or later it will also be the case in the rest of the world. In fact, several oral formulations of arsenic derivatives are currently in different stages of clinical development.

In China, four types of oral arsenic formulations have been used in APL: tetra-arsenic tetrathiosulfide (As₄S₄), ATO (As₂O₃), Qinghuang powder (realgar and indigo naturalis), and RIF (realgar, indigo naturalis formula, radix salviae miltiorrhizae, and radix pseudostellariae) [112]. Among them, only RIF is commercially available in China, but it has not been licensed elsewhere. This compound has not only demonstrated clinical efficacy comparable to intravenous ATO in two randomized studies in newly diagnosed APL, but also encompassed a better safety profile, improved quality of life, and lower costs [113,114]. In addition, at least three different formulations of oral ATO are being explored. A single-center study from Hong Kong using an oral formulation of ATO has provided excellent long-term outcomes in relapsed APL [115]. Data from a comparative bioavailability study developed in Australia (APML5; ACTRN12616001022459) have shown promising evidence of average bioequivalence between encapsulated oral and intravenous ATO [116]. Finally, a multicenter phase I study conducted in the USA with another oral ATO formulation (clinical trial registration # NCT03048344) has demonstrated that ORH-2014 at 15 mg is safe, bioavailable, and provides the required arsenic exposure compared to intravenous ATO at the approved dose (0.15 mg/kg) [117]. Certainly, these oral ATO formulations should be tested in prospective randomized studies. If their efficacy and safety profile is comparable to that of the intravenous preparations, oral ATO may be explored in an outpatient approach for the treatment of APL, especially for post-remission treatment.

CONFLICTS OF INTEREST

The authors declare they have no conflicts of interest.

AUTHORS’ CONTRIBUTION

Both authors contributed equally.

REFERENCES

[1] Bernard J. History of promyelocytic leukemia. Leukemia 1994;8:S1–S5.
[2] Pappenheim A. Uber die Wandlung des Lymphoïdozyten Begriffs und der Blatsmamm Zellen. Folia Haematol 1917;21:249–62.
[3] Pittaluga G. Sur les caractères cytologiques du “promyélocyte” et sur le hiatus leucémien. Sang 1940;14:325–41.
[4] Hillestad I.K. Acute promyelocytic leukemia. Acta Med Scand 1957;159:189–94.
[5] Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973;41:489–96.
[6] Caen JP, Mathé G, Xuan Chat L, Bernard J. Etude de la fibronélyse au cours des hémopathies malignes. Transcripts of the Sixth Congress of the European Society of Hematology. Copenhagen: Karger; 1957, pp. 502–6.
[7] Bernard J, Mathe G, Boulay J, Ceard B, Chome J. [Acute promyelocytic leukemia: a study made on 20 cases]. Schweiz Med Wochenschr 1959;89:604–8 (in French).
[8] Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451–8.
[9] Paitte E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994;8:968–73.
[10] Michieli M, Damiani D, Ermacora A, Geromin A, Michelutti A, Masolini P, et al. P-glycoprotein (Pgp), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukemia. Br J Haematol 2000;108:703–9.
[11] Takeshita A, Shinjo K, Naito K, Ohnishi K, Sugimoto Y, Yamakawa Y, et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol 2000;108:90–2.
[12] Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002;100:3141–6.
[13] Mandelli F, Labopin M, Granena A, Iriondo A, Prentice G, Bacigalupo A, et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant 1994;14:293–8.
Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–91.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naeo T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019;133:1630–43.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Acute Myeloid Leukemia (Version 3.2021) – March 2, 2021, (n.d.). Available from: https://www.nccn.org/guidelines/guidelines-detail?catego r=y=1&id=1411 (accessed April 7, 2021).

Sanz J, Montesinos P, Sanz MA. Role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Front Oncol 2021;11:614215.

Marty M, Ganem G, Fischer J, Flandrin G, Berger R, Schaison G, et al. [Acute promyelocytic leukaemia: retrospective study of 119 patients treated with daunorubicin]. Nouv Rev Fr Hematol 1984;26:371–8 (in French).

Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, et al. Acute promyelocytic leukaemia. M.D. Anderson Hospital experience. Am J Med 1986;80:789–97.

Golomb HM, Rowley J, Vardiman J, Baron J, Locker G, Krasnow S. Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia?. Arch Intern Med 1976;136:825–8.

Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977;309:549–50.

Rowley JD, Golomb HM, Vardiman J, Fukuhara S, Dougherty C, Potter D. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia. Int J Cancer 1977;20:689–72.

Fitzgerald PH, Fraser J, Beard MEJ. The geographical distribution of 15:17 translocation in acute promyelocytic leukemia. Cancer Genet Cytogenet 1981;1:273–4.

Teerenhovi L, Borgström GH, Mitelman F, Brandt L, Vuopio P, Timonen T, et al. Uneven geographical distribution of 15:17 translocation in acute promyelocytic leukemia. Lancet 1978;312:797.

Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15:17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827–41.

Grimsdale A, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, et al. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997;90:4876–85.

Grimsdale A, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic (15;17): results of the European Working Party, Groupe Français de Cytogénétique Hémato logic, Groupe de Français d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action “Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood 2000;96:1297–308.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. A variant form of hypergranular promyelo cytic leukemia (M3). Br J Haematol 1980;44:169–70.

Mattei MG, Petkovich M, Mattei JE, Brand N, Chambon P. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet 1988;80:186–8.

de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347:558–61.

Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:1577–80.

Longo L, Pandolfo PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F, et al. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 1990;172:1571–5.

de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675–84.

Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VVVS, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor. PML. Cell 1991;66:663–74.

Salomoni P, Pandolfo PP. The role of PML in tumor suppression. Cell 2002;108:165–70.

Lo Coco F, Diverio D, Avvisati G, Arcese W, Petti MC, Meloni G, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340:1437–8.

Biondi A, Rambaldi A, Pandolfo PP, Rossi V, Giudici G, Alcalay M, et al. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992;80:492–7.

Castaigne S, Balitrand N, de Thé H, Dejean A, Degos L, Chomienne C. A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992;79:3110–15.

Miller WH, Kakizuka A, Frankel SR, Warrell RP, DeBlasio A, Levine K, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukaemia. Proc Natl Acad Sci U S A 1992;89:2694–8.

Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of the rearranged RAR. Cell 1992;89:2694–8.

Chomienne C, Lanotte M, Degos L, de Thé H, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–91.

Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505–15.

Degos L. The history of acute promyelocytic leukaemia. Br J Haematol 2003;122:539–53.

Pierce GB, Verney EL. An in vitro and in vivo study of differentiation in teratocarcinomas. Cancer 1961;14:1017–29.

Schubert D, Humphreys S, de Vitry F, Jacob F. Induced differentiation of a neuroblastoma. Dev Biol 1971;25:514–46.

Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci U S A 1971;68:378–82.
[46] Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 1978;274:535–9.
[47] Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980;77:2936–40.
[48] Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemia cells in primary culture in response to retinoic acid. Blood 1981;57:1000–4.
[49] Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF. Retinoic acid treatment of acute promyelocytic leukaemia: in vitro and in vivo observations. Blood 1983;62:1211–17.
[50] Nilsson B. Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukemia. Br J Haematol 1984;57:365–71.
[51] Daenen S, Vellenga E, van Dobbenburgh OA, Halie MR. Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood 1986;67:559–61.
[52] Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukaemia. Report of 6 cases. Chin Med J (Engl) 1987;100:949–53.
[53] Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 1988;72:567–72.
[54] Wang ZY, Sun GL, Lu JX, Gu LJ, Huang ME, Chen SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouv Rev Fr Hematol 1990;32:34–6.
[55] Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991;78:1413–19.
[56] Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, et al. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 1990;336:1440–1.
[57] Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704–9.
[58] Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385–93.
[59] Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all-transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241–9.
[60] Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992;80:2176–81.
[61] Sun G, Ouyang R, Chen S, Juang G, Zhang T. Follow-up of 481 patients with APL after CR using ATRA. Chin J Hematol 1994;15:411–15.
[62] Warrell RP, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994;8:929–33.
[63] Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995;85:1202–6.
[64] Fenaux P, Chastang C, Chomienne C, Degos L. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia. Lancet 1994;343:1033.
[65] Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000;14:1371–7.
[66] Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021–8.
[67] Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, et al. All-trans retinoic acid for acute promyelocytic leukaemia: results of the New York Study. Ann Intern Med 1994;120:278–86.
[68] Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukaemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16:785–8.
[69] Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192–200.
[70] Mandelli F, Diverio D, Arvisiati L, Luciano A, Barbui T, Bernasconi C, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto e Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1999;90:1014–21.
[71] Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997;15:483–90.
[72] Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999;93:4131–43.
[73] Sanz MA, Martín G, Rayón C, Esteve J, González M, Diaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999;94:3015–21.
[74] Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löfler H, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 2000;14:1362–70.
[75] Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237–43.
[76] Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008;112;3130–4.

[77] Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115;5137–46.

[78] Lo-Cocco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010;116;3171–9.

[79] Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009;27;3650–8.

[80] Nagy I, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89;373–80.

[81] He LZ, Guizde F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet 1998;18;126–35.

[82] Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Genet 1998;18;126–35.

[83] Cioce M, et al. Fusion proteins of the retinoic acid receptor-Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Genet 1998;18;126–35.

[84] Co-repressors determine differential responses to RA in APL. Nat Genet 1998;391;815–8.

[85] Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR α chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000;5;821–30.

[86] Pandolfi PP. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet 2001;10;769–75.

[87] Lo-Cocco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol 2014;27;3–9.

[88] Abblain J, de Thé H. Retinoic acid signaling in cancer: the parable of acute promyelocytic leukemia. Int J Cancer 2013;155:2262–72.

[89] Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: assembly and oxidative stress-sensitive sumoylation. Cell 2004;116;3171–9.

[90] Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008;10;547–55.

[91] Sahin U, de Thé H, Lallemand-Breitenbach V. PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation. Nucleus 2014;5;499–507.

[92] Sun H, Ma L, Hu X, Zhang T. Treatment of acute promyelocytic leukemia by Ailing-I therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med 2012;12;170–2.

[93] Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As ) in the treatment of acute promyelocytic leukemia (APL): I. As , exerts dose-dependent dual effects on APL cells. Blood 1997;89;3345–53.

[94] Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As ) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89;3345–53.

[95] Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94;3315–24.

[96] Soignet SL, Maslak P, Wang ZG, Ihanwar S, Calleja E, Dardashiti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339;1341–8.

[97] Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19;3852–60.

[98] Zhang P, Wang S, Hu L. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17;58–62.

[99] Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As , combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101;5328–35.

[100] Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahanai M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006;17;131–4.

[101] Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006;107;2627–32.

[102] Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107;3469–73.
Iland H, Reynolds J, Boddy A, Khoo L, Yuen S, Bryant C, et al. Randomised, controlled trial of systemic retinoic acid for induction and consolidation therapy in acute promyelocytic leukemia. Haematologica 2000;85;17–23.

[110] Iacobelli S, de Witte T, Castoldi M, Willemze R, Orazi A, de Azambuja E, et al. Acute promyelocytic leukemia (AML 17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16;1295–305.

[111] Iland H, Reynolds J, Boddy A, Khoo L, Yuen S, Bryant C, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 2017;129;1275–83.

[112] Iacobelli S, de Witte T, Castoldi M, Willemze R, Orazi A, de Azambuja E, et al. Acute promyelocytic leukemia (AML 17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16;1295–305.

[113] Iacobelli S, de Witte T, Castoldi M, Willemze R, Orazi A, de Azambuja E, et al. Acute promyelocytic leukemia (AML 17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16;1295–305.

[114] Iacobelli S, de Witte T, Castoldi M, Willemze R, Orazi A, de Azambuja E, et al. Acute promyelocytic leukemia (AML 17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16;1295–305.